The FDA approved a new weight-loss pill in April 2026 that solves one of the most practical problems many patients have with existing oral GLP-1 therapy: you do not have to fast before taking it.
Foundayo (orforglipron), developed by Eli Lilly and approved by the FDA on April 1, 2026, is a once-daily oral GLP-1 receptor agonist that can be taken at any time of day — with food, without food, or with any beverage — with no timing restrictions whatsoever.
